Aaron P Thrift1,2, Elizabeth Y Chiao3,4. 1. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 2. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 3. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. echiao@bcm.edu. 4. Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, HSR&D Center of Innovation (152), 2002 Holcombe Boulevard, Houston, TX, 77030, USA. echiao@bcm.edu.
Abstract
PURPOSE OF REVIEW: The introduction of antiretroviral therapy (ART) has revolutionized HIV infection management, resulting in improved outcomes and survival for people living with HIV (PLWH). However, as PLWH are living longer and aging, non-AIDS-defining cancers (NADCs) represent a significant source of morbidity and mortality in the HIV-infected population. Here, we review the epidemiology of NADCs in PLWH. RECENT FINDINGS: Cancer mortality among PLWH is much higher than that among the general population. Up to 10% of deaths among PLWH have been attributed to NADCs. Furthermore, PLWH have an increased risk for specific NADCs, including lung cancer, hepatocellular carcinoma, head and neck cancers, anal cancer, and Hodgkin lymphoma. In the past decade, the incidence rates of AIDS-defining cancers (ADCs) have been decreasing while the incidence rates of NADCs have been increasing. In particular, the incidence of specific NADCs are changing at different rates. For example through 2010, the incidence rates for anal, liver, and prostate cancers among PLWH had increased, while incidence rates for lung cancer had decreased and incidence rates for colorectal cancer remained relatively stable over time. However, as early ART becomes more prevalent and the percentage of PLWH over 50 increases, these trends may evolve further. Incidence of NADCs should be expected to increase further as the PLWH population continues to age. Screening and prevention for these cancers among the HIV-infected population should be emphasized.
PURPOSE OF REVIEW: The introduction of antiretroviral therapy (ART) has revolutionized HIV infection management, resulting in improved outcomes and survival for people living with HIV (PLWH). However, as PLWH are living longer and aging, non-AIDS-defining cancers (NADCs) represent a significant source of morbidity and mortality in the HIV-infected population. Here, we review the epidemiology of NADCs in PLWH. RECENT FINDINGS: Cancer mortality among PLWH is much higher than that among the general population. Up to 10% of deaths among PLWH have been attributed to NADCs. Furthermore, PLWH have an increased risk for specific NADCs, including lung cancer, hepatocellular carcinoma, head and neck cancers, anal cancer, and Hodgkin lymphoma. In the past decade, the incidence rates of AIDS-defining cancers (ADCs) have been decreasing while the incidence rates of NADCs have been increasing. In particular, the incidence of specific NADCs are changing at different rates. For example through 2010, the incidence rates for anal, liver, and prostate cancers among PLWH had increased, while incidence rates for lung cancer had decreased and incidence rates for colorectal cancer remained relatively stable over time. However, as early ART becomes more prevalent and the percentage of PLWH over 50 increases, these trends may evolve further. Incidence of NADCs should be expected to increase further as the PLWH population continues to age. Screening and prevention for these cancers among the HIV-infected population should be emphasized.
Authors: Frank H Galvan; Eric G Bing; John A Fleishman; Andrew S London; Raul Caetano; M Audrey Burnam; Doug Longshore; Sally C Morton; Maria Orlando; Martin Shapiro Journal: J Stud Alcohol Date: 2002-03
Authors: Rennatus Mdodo; Emma L Frazier; Shanta R Dube; Christine L Mattson; Madeline Y Sutton; John T Brooks; Jacek Skarbinski Journal: Ann Intern Med Date: 2015-03-03 Impact factor: 25.391
Authors: Nancy A Hessol; Otoniel Martínez-Maza; Alexandra M Levine; Alison Morris; Joseph B Margolick; Mardge H Cohen; Lisa P Jacobson; Eric C Seaberg Journal: AIDS Date: 2015-06-19 Impact factor: 4.177
Authors: Eric A Engels; Malcolm V Brock; Jinbo Chen; Craig M Hooker; Maura Gillison; Richard D Moore Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Aaron P Thrift; Jennifer R Kramer; Christine M Hartman; Kathryn Royse; Peter Richardson; Yongquan Dong; Suchismita Raychaudhury; Roxanne Desiderio; Dina Sanchez; Sharmila Anandasabapathy; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Jeannette Y Lee; Shelly Y Lensing; J Michael Berry-Lawhorn; Naomi Jay; Teresa M Darragh; Stephen E Goldstone; Timothy J Wilkin; Elizabeth A Stier; Mark Einstein; Julia C Pugliese; Joel M Palefsky Journal: Contemp Clin Trials Date: 2022-01-10 Impact factor: 2.226
Authors: Rafael Ferreira E Costa; Marina Luiza Baião Leão; Maria Sissa Pereira Sant'Ana; Ricardo Alves Mesquita; Ricardo Santiago Gomez; Alan Roger Santos-Silva; Syed Ali Khurram; Artysha Tailor; Ciska-Mari Schouwstra; Liam Robinson; Willie F P van Heerden; Ramiro Alejandro Tomasi; Romina Gorrino; Ruth Salomé Ferreyra de Prato; Adalberto Mosqueda Taylor; José Manuel Aguirre Urizar; Irene Lafuente Ibañez de Mendoza; Raghu Radhakrishnan; Chetana Chandrashekar; Siu-Wai Choi; Peter Thomson; Hélder Antônio Rebelo Pontes; Felipe Paiva Fonseca Journal: Head Neck Pathol Date: 2022-03-22
Authors: Andrea M H Towlerton; Shashidhar Ravishankar; David G Coffey; Camille E Puronen; Edus H Warren Journal: Front Immunol Date: 2022-05-02 Impact factor: 8.786
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495